DDInter624 DDInter174
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatomegaly
Hepatomegaly {u} (Side Effect) is caused by {v} (Compound) Tioguanine
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Belinostat
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatomegaly
Hepatomegaly {u} (Side Effect) is caused by {v} (Compound) Lomitapide
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Belinostat
Efavirenz {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Belinostat
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Belinostat
Efavirenz {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Belinostat
Efavirenz {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Belinostat
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Belinostat
Efavirenz {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Belinostat
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Belinostat
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lomitapide
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Belinostat
Efavirenz (Compound) causes Hepatomegaly (Side Effect) and Hepatomegaly (Side Effect) is caused by Tioguanine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Efavirenz (Compound) causes Hepatomegaly (Side Effect) and Hepatomegaly (Side Effect) is caused by Lomitapide (Compound) and Lomitapide may lead to a major life threatening interaction when taken with Belinostat
Efavirenz (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Efavirenz (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Efavirenz (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is upregulated by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Efavirenz (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Belinostat
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Belinostat
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound) and Lomitapide may lead to a major life threatening interaction when taken with Belinostat